Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of SCT800 vs Xyntha in Hemophilia A
NCT02888223Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omfiloctocog alfa in hemophilia A (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Incremental Recovery (K-value), Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours and 2 more. Status: unknown.
02
Drugs
omfiloctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02888223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888223.